Continuation rates of alpha-blockers mono-therapy in adult men, prescribed by urologists or general practitioners: a pharmacy-based study

World J Urol. 2019 Aug;37(8):1659-1664. doi: 10.1007/s00345-018-2557-3. Epub 2018 Nov 13.

Abstract

Purpose: α-Blockers are commonly used for the treatment of male lower urinary tract symptoms (LUTS). The Dutch GP guideline on male LUTS contains an advice to discontinue treatment after 3-6 months of successful treatment. The guideline for urologists does not support this advice. It is unclear if these differences lead to other patterns of (dis)continuation of α-blockers. We aim to study continuation rates of α-blockers, prescribed by a urologist or a general practitioner (GP), and to predict discontinuation after 1 year.

Methods: We conducted a retrospective inception cohort study on prescription patterns of α-blockers among Dutch men between 2006 and 2014, using the IADB.nl pharmacy prescription database from the University of Groningen. We selected men aged 30 years or older with a first α-blocker prescription between 2006 and 2013, and analysed continuation of prescriptions.

Results: The database included 12,191 individual patients with at least one α-blocker prescriptions from a urologist (44.5%) or a GP (55.5%). The median treatment period for patients who started in the GPs office was 210 days, compared to 150 days for patients with a prescription from a urologist. Of all patients, 60.3% (GP prescriptions) and 66.1% (urologists' prescriptions) had discontinued treatment (Chi-square p < 0.001). Discontinuation rates were age dependent with higher rates in the youngest age groups.

Conclusion: In this study, the discontinuation rate 1 year after the initiation of treatment was high. Although Dutch GP's and urologist's guidelines differ with respect to a discontinuation advice, we could not find clinically relevant difference in (temporary) discontinuation rates.

Keywords: General practitioners; Lower urinary tract symptoms; Prescription patterns; Urologists; α-Blockers.

MeSH terms

  • Adrenergic alpha-Antagonists / administration & dosage*
  • Adult
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Drug Prescriptions / statistics & numerical data*
  • General Practice*
  • Humans
  • Lower Urinary Tract Symptoms / drug therapy*
  • Male
  • Middle Aged
  • Practice Patterns, Physicians'*
  • Retrospective Studies
  • Urology*
  • Withholding Treatment

Substances

  • Adrenergic alpha-Antagonists